Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 15,200 shares, an increase of 15.2% from the September 30th total of 13,200 shares. Based on an average daily trading volume, of 21,400 shares, the short-interest ratio is presently 0.7 days. Approximately 0.3% of the company’s shares are sold short.

Insiders Place Their Bets

In other news, Director Marc Duey bought 30,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was bought at an average cost of $4.39 per share, for a total transaction of $131,700.00. Following the completion of the acquisition, the director now directly owns 240,113 shares in the company, valued at $1,054,096.07. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. In other Aprea Therapeutics news, Director Bernd R. Seizinger purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The shares were purchased at an average cost of $2.68 per share, with a total value of $26,800.00. Following the completion of the transaction, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Marc Duey acquired 30,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were acquired at an average price of $4.39 per share, with a total value of $131,700.00. Following the completion of the transaction, the director now directly owns 240,113 shares in the company, valued at approximately $1,054,096.07. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 42,290 shares of company stock worth $165,096. Company insiders own 12.80% of the company’s stock.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Price Performance

Shares of NASDAQ APRE opened at $4.28 on Tuesday. Aprea Therapeutics has a one year low of $2.15 and a one year high of $8.85. The business’s 50-day moving average price is $3.28 and its two-hundred day moving average price is $4.06. The company has a market capitalization of $23.24 million, a P/E ratio of -1.29 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.05. The business had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.10 million. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. On average, equities analysts anticipate that Aprea Therapeutics will post -2.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a research report on Thursday, October 24th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.